Impact of pyrazinamide resistance on multidrug-resistant tuberculosis in Karakalpakstan, Uzbekistan
نویسندگان
چکیده
منابع مشابه
Modelling the effect of short-course multidrug-resistant tuberculosis treatment in Karakalpakstan, Uzbekistan
BACKGROUND Multidrug-resistant tuberculosis (MDR-TB) is a major threat to global TB control. MDR-TB treatment regimens typically have a high pill burden, last 20 months or more and often lead to unsatisfactory outcomes. A 9-11 month regimen with seven antibiotics has shown high success rates among selected MDR-TB patients in different settings and is conditionally recommended by the World Healt...
متن کاملMultidrug-Resistant Tuberculosis Treatment Outcomes in Karakalpakstan, Uzbekistan: Treatment Complexity and XDR-TB among Treatment Failures
BACKGROUND A pilot programme to treat multidrug-resistant TB (MDR-TB) was implemented in Karakalpakstan, Uzbekistan in 2003. This region has particularly high levels of MDR-TB, with 13% and 40% among new and previously treated cases, respectively. METHODOLOGY This study describes the treatment process and outcomes for the first cohort of patients enrolled in the programme, between October 200...
متن کاملMultidrug-resistant tuberculosis in Uzbekistan: results
D J Ulmasova1, G Uzakova2, M N Tillyashayhov3, L Turaev4, W van Gemert5, H Hoffmann6, M Zignol5, K Kremer7, T Gombogaram8, J Gadoev8, P du Cros9, N Muslimova4, A Jalolov2, A Dadu7, P de Colombani7, O Telnov10, A Slizkiy10, B Kholikulov1, M Dara7, D Falzon ([email protected])5 1. Republican DOTS Centre, Tashkent, Uzbekistan 2. Programme Implementation Unit, The Global Fund to Fight AIDS, TB and Ma...
متن کاملPyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates.
Pyrazinamide is important in tuberculosis treatment, as it is bactericidal to semidormant mycobacteria not killed by other antituberculosis drugs. Pyrazinamide is also one of the cornerstone drugs retained in the treatment of multidrug-resistant tuberculosis (MDR-TB). However, due to technical difficulties, routine drug susceptibility testing of Mycobacterium tuberculosis for pyrazinamide is, i...
متن کاملPyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis.
The role of pyrazinamide in the current treatment of multidrug-resistant (MDR) tuberculosis (TB) is uncertain. From a territory-wide registry of MDR-TB cases diagnosed between 1995 and 2009, we assembled a cohort of 194 patients with MDR pulmonary TB given fluoroquinolone-containing regimens. Stratified by pyrazinamide use and susceptibility, there were 83 users with pyrazinamide-susceptible MD...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The International Journal of Tuberculosis and Lung Disease
سال: 2018
ISSN: 1027-3719
DOI: 10.5588/ijtld.17.0483